4547:TYO
Kissei Pharmaceutical Co Ltd
3Â 830,00Â JPÂ¥
0,00%
(0,00) 1K
1-okt, 15:30:00 (GMT+9) · JPY
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_auto4547 tikeri uchun statistika yaratilmoqda...
Bozor kapitali
178,26Â mlrd
Oʻrtacha hajm
66,55Â ming
Hajmi
0,00
Dividend
3,13%
Choraklik dividendlar
30Â JPÂ¥
Eks-dividend sanasi
29-sen, 2026
P/E koeffitsiyenti
11,35
52 haftalik eng yuqori
5Â 040Â JPÂ¥
52 haftalik eng past
3Â 500Â JPÂ¥
Aksiya boʻyicha daromad
337Â JPÂ¥
Muomaladagi aksiyalar
46,72Â mln
Xodimlar soni
2Â ming
Bozor kapitali
178,26Â mlrd
Oʻrtacha hajm
66,55Â ming
Hajmi
0,00
Dividend
3,13%
Choraklik dividendlar
30Â JPÂ¥
Eks-dividend sanasi
29-sen, 2026
P/E koeffitsiyenti
11,35
52 haftalik eng yuqori
5Â 040Â JPÂ¥
52 haftalik eng past
3Â 500Â JPÂ¥
Aksiya boʻyicha daromad
337Â JPÂ¥
Muomaladagi aksiyalar
46,72Â mln
Xodimlar soni
2Â ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
MarketBeat
·
17 daqiqa oldin
Insider Buying: PodcastOne (NASDAQ:PODC) Director Purchases 7,000 Shares of Company Stock
Nasdaq
·
32 daqiqa oldin
A Quarter of Companies Have No Analyst Coverage
MarketWatch
·
21 daqiqa oldin
Here’s who’s joining the S&P 500 in the index’s latest shakeup
Yahoo Finance
·
2 soat oldin
Why this analyst sees 15% upside for the S&P 500
Profil
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
Kissei Pharmaceutical Co Ltd haqida
CEOMutsuo Kanzawa
Xodimlar soni1,79Â ming
Asos solingan9-avg, 1946
Bosh ofislarMatsumoto, Nagano, Yaponiya
Sektor-
Veb-saytkissei.co.jp